Importer of Controlled Substances Application: United States Pharmacopeial Convention, 23582-23583 [2019-10668]
Download as PDF
<![CDATA[
23582
Federal Register / Vol. 84, No. 99 / Wednesday, May 22, 2019 / Notices
Company
FR docket
Meridian Medical Technologies .......................................................................................................
Organic Standards Solutions International, LLC .............................................................................
SpecGx LLC ....................................................................................................................................
84 FR 7129 ...............
84 FR 13958 .............
84 FR 13954 .............
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrants to import the
applicable basic classes of schedule I
and II controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated each of the company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I and schedule II controlled
substances to the above listed
companies.
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on March
8, 2019, United States Pharmacopeial,
12601 Twinbrook Parkway, Rockville,
Maryland 20852–1717 applied to be
registered as an importer of the
following basic classes of controlled
substances:
Dated: May 7, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–10669 Filed 5–21–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: United States
Pharmacopeial Convention
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 21, 2019. Such persons
may also file a written request for a
hearing on the application on or before
June 21, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
DATES:
jbell on DSK3GLQ082PROD with NOTICES
Controlled substance
17:29 May 21, 2019
Jkt 247001
PO 00000
Frm 00061
Fmt 4703
March 1, 2019.
April 8, 2019.
April 8, 2019.
Drug code
Methamphetamine ...........................................................................................................................................................
Cathinone ........................................................................................................................................................................
Phenmetrazine .................................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Glutethimide .....................................................................................................................................................................
Methaqualone ..................................................................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine .............................................................................................................................
3,4-Methylenedioxyamphetamine ....................................................................................................................................
4-Methoxyamphetamine ..................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Phenylacetone .................................................................................................................................................................
Alphaprodine ....................................................................................................................................................................
Anileridine ........................................................................................................................................................................
Cocaine ............................................................................................................................................................................
Codeine-N-oxide ..............................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Difenoxin ..........................................................................................................................................................................
Diphenoxylate ..................................................................................................................................................................
Heroin ..............................................................................................................................................................................
Levomethorphan ..............................................................................................................................................................
Levorphanol .....................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
VerDate Sep<11>2014
Published
Sfmt 4703
E:\FR\FM\22MYN1.SGM
22MYN1
1105
1235
1631
1724
2125
2270
2315
2550
2565
7315
7395
7400
7411
7471
8333
8501
9010
9020
9041
9053
9120
9168
9170
9200
9210
9220
9230
9273
Schedule
II
I
II
II
II
II
II
II
I
I
I
I
I
II
II
II
II
II
II
I
II
I
II
I
II
II
II
II
23583
Federal Register / Vol. 84, No. 99 / Wednesday, May 22, 2019 / Notices
Controlled substance
Drug code
Morphine-N-oxide ............................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Norlevorphanol ................................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
The company plans to import the bulk
control substances for distribution of
analytical reference standards to its
customers for analytical testing of raw
materials.
DEPARTMENT OF JUSTICE
Dated: May 7, 2019.
John J. Martin,
Assistant Administrator.
On May 16, 2019, the Department of
Justice lodged a proposed Stipulation of
Settlement and Order (‘‘Agreement’’)
with the United States District Court for
the District of Massachusetts in the
lawsuit entitled United States v. Kayem
Foods, Inc., Civil Action No. 1:19–cv–
11126.
In this action, the United States filed
a complaint alleging that Kayem Foods,
Inc. (‘‘Kayem’’) violated Section
112(r)(7) of the Clean Air Act, 42 U.S.C.
7412(r)(7), at Kayem’s food processing
facility located in Chelsea,
Massachusetts. Section 112(r)(7) of the
CAA, 42 U.S.C. 7412(r)(7), provides that
the Administrator of the EPA is
authorized to promulgate regulations
requiring owners or operators of a
stationary source at which a regulated
substance is present in more than a
threshold amount to, among other
things, prepare and implement a risk
management plan to detect and prevent
or minimize accidental releases of
regulated substances from the stationary
source, and to provide a prompt
emergency response to any such
releases in order to protect human
health and the environment. EPA has
promulgated regulations to implement
Section 112(r)(7), codified at 40 CFR
part 68 (‘‘Part 68 Regulations’’). The
Complaint alleges that Kayem violated
the Part 68 Regulations in connection
with the operation of its ammonia
refrigeration system at its Chelsea
facility and seeks the payment of civil
penalties.
The proposed Agreement resolves
Kayem’s civil liability to the United
States for the alleged violations in the
Complaint. Pursuant to the proposed
Agreement, Kayem will pay a penalty of
$138,281. Injunctive relief is not
required.
The publication of this notice opens
a period for public comment on the
Agreement. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
[FR Doc. 2019–10668 Filed 5–21–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Foreign Claims Settlement
Commission
[F.C.S.C. Meeting and Hearing Notice No.
04–19]
jbell on DSK3GLQ082PROD with NOTICES
Sunshine Act Meeting
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR part 503.25) and the
Government in the Sunshine Act (5
U.S.C. 552b), hereby gives notice in
regard to the scheduling of open
meetings as follows:
TIME AND DATE: Thursday, May 30, 2019,
at 10:00 a.m.
PLACE: All meetings are held at the
Foreign Claims Settlement Commission,
601 D Street NW, Suite 10300,
Washington, DC.
STATUS: Open.
MATTERS TO BE CONSIDERED: 10:00
a.m.—Oral hearings on Objection to
Commission’s Proposed Decisions in
Claim Nos. IRQ–II–346 and IRQ–II–365.
11:30 a.m.—Issuance of Proposed
Decisions under the Guam World War II
Loyalty Recognition Act, Title XVII,
Public Law 114–328.
CONTACT PERSON FOR MORE INFORMATION:
Requests for information, or advance
notices of intention to observe an open
meeting, may be directed to: Patricia M.
Hall, Foreign Claims Settlement
Commission, 601 D Street NW, Suite
10300, Washington, DC 20579.
Telephone: (202) 616–6975.
Brian Simkin,
Chief Counsel.
[FR Doc. 2019–10735 Filed 5–20–19; 11:15 am]
BILLING CODE 4410–BA–P
VerDate Sep<11>2014
17:29 May 21, 2019
Jkt 247001
Notice of Lodging of Proposed
Settlement Agreement Under the Clean
Air Act
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
9307
9333
9634
9652
9668
9737
9740
Schedule
I
II
II
II
II
II
II
United States v. Kayem Foods, Inc.. No.
1:19–cv–11126 (D. Mass.) D.J. Ref. No.
90–5–2–1–11490. All comments must be
submitted no later than thirty (30) days
after the publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By email .......
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
During the public comment period,
the Agreement may be examined and
downloaded at this Justice Department
website: https://www.justice.gov/enrd/
consent-decrees. We will provide a
paper copy of the Agreement upon
written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
Please enclose a check or money order
for $2.75 (25 cents per page
reproduction cost) payable to the United
States Treasury.
Robert Maher,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2019–10673 Filed 5–21–19; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Agency Information Collection
Activities; Comment Request; State
Training Provider Eligibility Collection
ACTION:
Notice.
The Department of Labor’s
(DOL’s), Employment and Training
Administration (ETA) is soliciting
comments concerning a proposed
extension for the authority to conduct
the information collection request (ICR)
titled, ‘‘State Training Provider
SUMMARY:
E:\FR\FM\22MYN1.SGM
22MYN1
]]>Agencies
[Federal Register Volume 84, Number 99 (Wednesday, May 22, 2019)]
[Notices]
[Pages 23582-23583]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10668]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: United States
Pharmacopeial Convention
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before June 21, 2019. Such
persons may also file a written request for a hearing on the
application on or before June 21, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on March
8, 2019, United States Pharmacopeial, 12601 Twinbrook Parkway,
Rockville, Maryland 20852-1717 applied to be registered as an importer
of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Methamphetamine.......................... 1105 II
Cathinone................................ 1235 I
Phenmetrazine............................ 1631 II
Methylphenidate.......................... 1724 II
Amobarbital.............................. 2125 II
Pentobarbital............................ 2270 II
Secobarbital............................. 2315 II
Glutethimide............................. 2550 II
Methaqualone............................. 2565 I
Lysergic acid diethylamide............... 7315 I
4-Methyl-2,5-dimethoxyamphetamine........ 7395 I
3,4-Methylenedioxyamphetamine............ 7400 I
4-Methoxyamphetamine..................... 7411 I
Phencyclidine............................ 7471 II
4-Anilino-N-phenethyl-4-piperidine (ANPP) 8333 II
Phenylacetone............................ 8501 II
Alphaprodine............................. 9010 II
Anileridine.............................. 9020 II
Cocaine.................................. 9041 II
Codeine-N-oxide.......................... 9053 I
Dihydrocodeine........................... 9120 II
Difenoxin................................ 9168 I
Diphenoxylate............................ 9170 II
Heroin................................... 9200 I
Levomethorphan........................... 9210 II
Levorphanol.............................. 9220 II
Meperidine............................... 9230 II
Dextropropoxyphene, bulk (non-dosage 9273 II
forms).
[[Page 23583]]
Morphine-N-oxide......................... 9307 I
Thebaine................................. 9333 II
Norlevorphanol........................... 9634 II
Oxymorphone.............................. 9652 II
Noroxymorphone........................... 9668 II
Alfentanil............................... 9737 II
Sufentanil............................... 9740 II
------------------------------------------------------------------------
The company plans to import the bulk control substances for
distribution of analytical reference standards to its customers for
analytical testing of raw materials.
Dated: May 7, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-10668 Filed 5-21-19; 8:45 am]
BILLING CODE 4410-09-P
